作者：
Harstad,E.B. [1]
;
Rosenblum,J.S. [2]
;
Gorrell,M.D. [3]
;
Achanzar,W.E. [4]
;
Minimo,L. [5]
;
Wu,J. [6]
;
Rosini-Marthaler,L. [7]
;
Gullo,R. ;
Ordway,N.D. ;
Kirby,M.S. ;
Chadwick,K.D. ;
Cosma,G.N. ;
Moyer,C.F.
作者单位：
Drug Safety Evaluation, Bristol-Myers Squibb Co., New Brunswick, NJ, United States, CBSS, Amgen
[1]
Drug Safety Evaluation, Bristol-Myers Squibb Co., New Brunswick, NJ, United States, Safety
[2]
ActivX Biosciences, Inc., La Jolla, CA, United States
[3]
Centenary Institute DO6, Sydney Medical School, University of Sydney, NSW 2006, Australia
[4]
ActivX Biosciences, Inc., La Jolla, CA, United States, St. Francis De Sales Center for Priestly
[5]
Discovery Biology, Bristol-Myers Squibb Co., Princeton, NJ, United States
[6]
Drug Safety Evaluation, Bristol-Myers Squibb Co., New Brunswick, NJ, United States
[7]
发布时间
2013-12-28
换一批
